Dr Christine Anne Meore, PT, DPT | |
34 Maple Brook Rd, Tuxedo, NY 10987 | |
(845) 521-8697 | |
Not Available |
Full Name | Dr Christine Anne Meore |
---|---|
Gender | Female |
Speciality | Physical Therapist |
Location | 34 Maple Brook Rd, Tuxedo, New York |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1356947758 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
225100000X | Physical Therapist | 046407 (New York) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Christine Anne Meore, PT, DPT 34 Maple Brook Rd, Tuxedo, NY 10987 Ph: (845) 521-8697 | Dr Christine Anne Meore, PT, DPT 34 Maple Brook Rd, Tuxedo, NY 10987 Ph: (845) 521-8697 |
News Archive
Some Democrats fretted over cuts to the health care law to help pay for the package; physician groups were disappointed it did not replace Medicare's sustainable growth rate formula.
Mice with epilepsy have altered patterns of neuron activity in the portion of the brain that controls the reproductive endocrine system, University of Illinois researchers report in a new study. Furthermore, the differences in neuron activity in female mice fluctuate across the reproductive cycle, the team found.
Children's Hospital Los Angeles physician-scientist Roger E. De Filippo, MD, an associate professor of urology and director of Pediatric Urology Stem Cell Research at the Keck School of Medicine of the University of Southern California discusses how science, technology and parental care can lead to improved pediatric urological health.
K7 LLC's K7C Cervical Spacer, a spinal implant device using Evonik's VESTAKEEP PEEK (polyetheretherketone), has received the U.S. Food and Drug Administration's (FDA) 510(k) approval for use as an Intervertebral Body Fusion (IBF) device.
Aerovance Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial, of inhaled dry powder Aerovant in patients with uncontrolled asthma.
› Verified 6 days ago